Sanofi to Appeal Delaware Court’s Decision on Zantac
Sanofi has expressed disappointment with the recent decision by the State of Delaware court and intends to appeal. The company maintains that there is no reliable scientific evidence linking Zantac to cancer, a stance supported by a 2022 ruling from a US federal court in Florida overseeing federal cases in multidistrict litigation. Prior to this Delaware decision, around 75,000 individuals had filed lawsuits in Delaware, with approximately 25,000 naming Sanofi and almost all including additional defendants. Sanofi believes that none of these cases should proceed to trial. The company remains committed to defending Zantac’s safety and will continue to vigorously contest these claims, which have been extensively evaluated and deemed without merit by medical, scientific, and regulatory communities.
Sanofi is an innovative global healthcare company with a mission to harness the miracles of science to improve lives. Our dedicated team worldwide is focused on transforming medical practices by making the impossible possible. We offer life-changing treatment options and life-saving vaccines to millions globally, prioritizing sustainability and social responsibility in all our endeavors. Sanofi is publicly traded on EURONEXT: SAN and NASDAQ: SNY.
Sanofi Forward-Looking Statements
This media update includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, as amended. These statements are not historical facts but rather projections and estimates about the product’s marketing potential and future revenue. Forward-looking statements often include terms such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” and similar expressions. While Sanofi’s management believes the expectations in these forward-looking statements are reasonable, they are subject to various risks and uncertainties that are difficult to predict and generally beyond Sanofi’s control. These risks include unexpected regulatory actions or delays, government regulations affecting product availability or commercial potential, commercial success, research and development uncertainties, post-marketing clinical data, safety, quality or manufacturing issues, competition, intellectual property risks and related litigation outcomes, volatile economic and market conditions, and impacts from pandemics or global crises on Sanofi, its stakeholders, and the global economy. These risks and uncertainties are detailed in Sanofi’s public filings with the SEC and AMF, including the “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” sections of Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Except as required by law, Sanofi does not undertake to update or revise any forward-looking statements.
